--- title: "AllianceBernstein (NYSE:AB) Stock Price Expected to Rise, Barclays Analyst Says" description: "Barclays has raised its price target for AllianceBernstein (NYSE:AB) from $34.00 to $36.00, maintaining an \"equal weight\" rating. This suggests a potential downside of 3.05% from the current price. Ot" type: "news" locale: "en" url: "https://longbridge.com/en/news/236590421.md" published_at: "2025-04-18T13:02:13.000Z" --- # AllianceBernstein (NYSE:AB) Stock Price Expected to Rise, Barclays Analyst Says > Barclays has raised its price target for AllianceBernstein (NYSE:AB) from $34.00 to $36.00, maintaining an "equal weight" rating. This suggests a potential downside of 3.05% from the current price. Other brokerages have also adjusted their ratings, with Evercore ISI setting a target of $38.00 and Bank of America lowering theirs to $38.00 as well. AllianceBernstein's stock opened at $37.13, with a 1-year range of $30.57 to $41.37. Analysts predict earnings per share of 3.58 for the current year. AllianceBernstein (NYSE:AB - Get Free Report) had its price objective boosted by equities research analysts at Barclays from $34.00 to $36.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an "equal weight" rating on the asset manager's stock. Barclays's price target suggests a potential downside of 3.05% from the company's current price. Get **AllianceBernstein** alerts: - 3 Biopharmaceutical Stocks Bucking the Sell-Off Several other brokerages also recently issued reports on AB. Evercore ISI reduced their price objective on AllianceBernstein from $41.00 to $38.00 and set an "outperform" rating for the company in a research note on Friday, April 11th. Bank of America lowered shares of AllianceBernstein from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $42.00 to $38.00 in a research note on Thursday, April 3rd. Sanford C. Bernstein cut shares of AllianceBernstein from a "buy" rating to a "neutral" rating and set a $38.00 price objective for the company. in a report on Thursday, April 3rd. Finally, TD Cowen lowered their price objective on AllianceBernstein from $37.50 to $34.00 and set a "hold" rating on the stock in a report on Wednesday, April 9th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $37.50. **Read Our Latest Research Report on AllianceBernstein** ## AllianceBernstein Trading Down 1.7 % - MarketBeat Week in Review – 03/24 - 03/28 Shares of AB opened at $37.13 on Wednesday. AllianceBernstein has a 1-year low of $30.57 and a 1-year high of $41.37. The stock has a market capitalization of $4.10 billion, a P/E ratio of 9.98, a P/E/G ratio of 0.78 and a beta of 0.97. The business's 50-day moving average price is $36.99 and its 200 day moving average price is $36.94. AllianceBernstein (NYSE:AB - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The asset manager reported $1.05 EPS for the quarter, beating the consensus estimate of $0.87 by $0.18. AllianceBernstein had a net margin of 9.46% and a return on equity of 17.88%. On average, research analysts predict that AllianceBernstein will post 3.58 earnings per share for the current year. ## Institutional Trading of AllianceBernstein - AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market A number of hedge funds have recently modified their holdings of the company. FMR LLC lifted its holdings in shares of AllianceBernstein by 19.0% during the 4th quarter. FMR LLC now owns 3,110,304 shares of the asset manager's stock worth $115,361,000 after acquiring an additional 496,923 shares during the period. American Century Companies Inc. boosted its holdings in AllianceBernstein by 1.1% during the fourth quarter. American Century Companies Inc. now owns 3,026,102 shares of the asset manager's stock valued at $112,238,000 after purchasing an additional 33,888 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of AllianceBernstein by 18.1% in the 4th quarter. JPMorgan Chase & Co. now owns 2,899,762 shares of the asset manager's stock worth $107,552,000 after buying an additional 445,398 shares in the last quarter. Jennison Associates LLC boosted its stake in AllianceBernstein by 7.0% in the 4th quarter. Jennison Associates LLC now owns 939,649 shares of the asset manager's stock valued at $34,852,000 after buying an additional 61,326 shares in the last quarter. Finally, Natixis grew its position in AllianceBernstein by 16.4% in the fourth quarter. Natixis now owns 660,700 shares of the asset manager's stock valued at $24,505,000 after acquiring an additional 93,300 shares during the period. Institutional investors own 19.25% of the company's stock. ## About AllianceBernstein (Get Free Report) AllianceBernstein Holding L.P. is a publicly owned investment manager. The firm is a related adviser The firm manages separate client focused portfolios for its clients. The firm primarily invests in common and preferred stocks, warrants and convertible securities, government and corporate fxed-income securities, commodities, currencies, real estate-related assets and infation-protected securities. ## Featured Articles - Five stocks we like better than AllianceBernstein - What Are Dividend Contenders? Investing in Dividend Contenders - 3 High-Value Companies With Triple-Digit Upside Potential - Options Trading - Understanding Strike Price - Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? - The Top 3 Healthcare Dividend Stocks to Buy and Hold - The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in AllianceBernstein Right Now? Before you consider AllianceBernstein, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AllianceBernstein wasn't on the list. While AllianceBernstein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [AB.US - AllianceBernstein](https://longbridge.com/en/quote/AB.US.md) - [BCS.US - Barclays](https://longbridge.com/en/quote/BCS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | ETAB Electrolux 于 04:34 发布 2025 年年度报告 | AB Electrolux 发布了其 2025 年度报告，强调有机销售增长 3.9%，主要来自北美和拉丁美洲。尽管面临关税和货币波动的挑战，营业收入仍上升至 37 亿瑞典克朗，利润率为 2.8%。报告概述了一项以消费者偏好、生命周期价值创造 | [Link](https://longbridge.com/en/news/276318781.md) | | AB 志愿者为慕尼黑有需要的年轻人提供支持 | AllianceBernstein (AB) 的志愿者最近在慕尼黑支持有需要的年轻人，组织了一个工作站并为 Arche Kinderstiftung 修理自行车。此外，AB 日本还为高中生举办了一场金融教育活动，而西棕榈滩办公室则在 Qua | [Link](https://longbridge.com/en/news/276134263.md) | | REG - AllianceBernstein LP Just Group plc - 表格 8.3 - Just Group PLC | AllianceBernstein L.P. 于 2026 年 2 月 17 日披露了其在 Just Group PLC 的持仓情况。该公司持有 132,877 股（0.01%）和现金结算衍生品总计 14,073,781 股（1.35%）， | [Link](https://longbridge.com/en/news/276226938.md) | | Stonegate Capital Partners 开始对 AB Science SA 进行研究覆盖 | Stonegate Capital Partners 已经开始对 AB Science S.A. (ENXTPA: AB) 进行覆盖，该生物技术公司专注于用于 ALS、进行性多发性硬化症和阿尔茨海默病的 masitinib，并在急性髓性白血 | [Link](https://longbridge.com/en/news/275479019.md) | | REG - AllianceBernstein LP Just Group plc - 表格 8.3 - Just Group PLC | AllianceBernstein L.P. 于 2026 年 2 月 10 日披露了其在 Just Group PLC 的持仓。该公司持有 132,877 股（0.01%）和现金结算的衍生品总计 13,754,262 股（1.32%），总 | [Link](https://longbridge.com/en/news/275619042.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.